PMDA drug package insert
ピオグリタゾンOD錠15mg「NS」
PMDA Prescription drug · 日新製薬株式会社 · package insert Mar 30, 2026
Key facts
| Brand names | ピオグリタゾンOD錠15mg「NS」, ピオグリタゾンOD錠30mg「NS」 |
|---|---|
| Nonproprietary names | ピオグリタゾン塩酸塩 |
| Companies | 製造販売元／日新製薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | インスリン抵抗性改善剤 -2型糖尿病治療剤- |
| Therapeutic category codes | 873969 |
| YJ codes | 3969007F3060, 3969007F4066 |
| Approval numbers | 22300AMX00132, 22300AMX00134 |
| Package insert edition | 第2版 |
| Package insert date | Mar 30, 2026 |
| PMDA document key | 530113_3969007F3060_1 |
| PMDA company code | 530113 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- 1–9 Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: